June 12, 2019 — Boston Scientific Corp. has initiated the OPTION trial to compare safety and effectiveness of the next ...
Pharmaceuticals
This channel includes news and new technology innovations for cardiovascular pharmaceutics. This includes antiplatelet agents, anticoagulation drugs, INR testing, NOAC, OAC, IV administered drugs such as Heprin, and dual antiplatelet therapy.
June 12, 2019
May 29, 2019 — Amarin Corp. plc announced that its supplemental new drug application (sNDA) for Vascepa (icosapent ethyl ...
May 29, 2019
May 17, 2019 — The U.S. Food and Drug Administration (FDA) this week approved Fragmin (dalteparin sodium) injection, for ...
May 17, 2019
May 6, 2019 — The U.S. Food and Drug Administration (FDA) approved tafamidis meglumine (Vyndaqel) and tafamidis ...
May 06, 2019
April 30, 2019 — PhaseBio Pharmaceuticals Inc. announced the U.S. Food and Drug Administration (FDA) has granted ...
April 30, 2019
This video offers an overview of the Watchman left atrial appendage (LAA) occluder system, including information of its ...
April 25, 2019
April 24, 2019 — New research from the University of Illinois at Chicago shows that when pharmacies close, people stop ...
April 24, 2019
April 19, 2019 – Researchers at the Icahn School of Medicine at Mount Sinai have demonstrated that the recently ...
April 19, 2019
April 18, 2019 — A recent study found patients with atherosclerotic cardiovascular disease cut their risk of a second ...
April 18, 2019
April 16, 2019 — HonorHealth Research Institute announced the first patients have been enrolled in the SynIVUS-DAPT ...
April 16, 2019
April 15, 2019 — Despite national guidelines indicating statins can lower risk of heart attack and stroke, many patients ...
April 15, 2019
March 29, 2019 — The cardiovascular benefits of the diabetes drug dapagliflozin extend across a wide spectrum of ...
March 29, 2019
March 29, 2019 — Taking a high dose of icosapent ethyl significantly reduces the occurrence of first, subsequent and ...
March 29, 2019![New data from a four-week extension of the landmark PIONEER-HF Trial showed the drug sacubitril/valsartan (Entresto) continued to deliver reductions in the heart failure biomarker N-terminal pro–B-type natriuretic peptide (NT-proBNP), an established biomarker for heart failure severity and prognosis.[1] The data was presented as a late-breaker at the American College of Cardiology (ACC) 2019 Annual Scientific Session in March.](/sites/default/files/styles/content_feed_medium/public/Entresto_bottles.jpg?itok=sp56E5GI)
March 27, 2019 —New data from a four-week extension of the landmark PIONEER-HF Trial showed the drug sacubitril ...
March 27, 2019
March 25, 2019 — Patients who stopped taking aspirin one month after receiving a stent in the heart’s arteries but ...
March 25, 2019© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now